150 related articles for article (PubMed ID: 34526424)
21. Risk factors for hypothyroidism and thyroid hormone replacement after hemithyroidectomy in papillary thyroid carcinoma.
Lee SJ; Song CM; Ji YB; Choi YY; Sohn YS; Park JH; Kim DS; Tae K
Langenbecks Arch Surg; 2021 Jun; 406(4):1223-1231. PubMed ID: 33970335
[TBL] [Abstract][Full Text] [Related]
22. Oncological impact of hypothyroidism and levothyroxine supplementation following hemithyroidectomy in patients with papillary thyroid carcinoma.
Ahn D; Lee GJ; Sohn JH; Jeon JH
Head Neck; 2020 May; 42(5):1004-1013. PubMed ID: 31930773
[TBL] [Abstract][Full Text] [Related]
23. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study.
Sugitani I; Fujimoto Y
Surgery; 2011 Dec; 150(6):1250-7. PubMed ID: 22136848
[TBL] [Abstract][Full Text] [Related]
24. Thyroid Laboratory Testing and Management in Women on Thyroid Replacement Before Pregnancy and Associated Pregnancy Outcomes.
Lemieux P; Yamamoto JM; Nerenberg KA; Metcalfe A; Chin A; Khurana R; Donovan LE
Thyroid; 2021 May; 31(5):841-849. PubMed ID: 33108964
[No Abstract] [Full Text] [Related]
25. Clinical Features of Early and Late Postoperative Hypothyroidism After Lobectomy.
Park S; Jeon MJ; Song E; Oh HS; Kim M; Kwon H; Kim TY; Hong SJ; Shong YK; Kim WB; Sung TY; Kim WG
J Clin Endocrinol Metab; 2017 Apr; 102(4):1317-1324. PubMed ID: 28324106
[TBL] [Abstract][Full Text] [Related]
26. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
27. The different requirement of L-T4 therapy in congenital athyreosis compared with adult-acquired hypothyroidism suggests a persisting thyroid hormone resistance at the hypothalamic-pituitary level.
Bagattini B; Cosmo CD; Montanelli L; Piaggi P; Ciampi M; Agretti P; Marco GD; Vitti P; Tonacchera M
Eur J Endocrinol; 2014 Nov; 171(5):615-21. PubMed ID: 25305309
[TBL] [Abstract][Full Text] [Related]
28. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of L-thyroxine treatment on TSH suppression during pregnancy in patients with a history of thyroid carcinoma after total thyroidectomy and radioiodine ablation.
Krhin B; Besic N
Radiol Oncol; 2012 Jun; 46(2):160-5. PubMed ID: 23077453
[TBL] [Abstract][Full Text] [Related]
30. Naming difficulties after thyroid stimulating hormone suppression therapy in patients with differentiated thyroid carcinoma: a prospective cohort study.
Jin S; Yang YT; Bao W; Bai Y; Ai JW; Liu Y; Yong H
Endocrine; 2019 Aug; 65(2):327-337. PubMed ID: 31056722
[TBL] [Abstract][Full Text] [Related]
31. [Evaluation of the optimal thyroxine dose with the TRH test for replacement and suppression therapy].
Erne P; Staub JJ; Althaus B; Fleig Y; Girard J
Schweiz Med Wochenschr; 1983 Dec; 113(50):1922-3. PubMed ID: 6420884
[TBL] [Abstract][Full Text] [Related]
32. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.
Fussey JM; Khan H; Ahsan F; Prashant R; Pettit L
Head Neck; 2017 Dec; 39(12):2567-2572. PubMed ID: 28960722
[TBL] [Abstract][Full Text] [Related]
33. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.
Xiao L; Wu J; Jiang L; Xu Y; Liu B
Clin Endocrinol (Oxf); 2022 Mar; 96(3):413-418. PubMed ID: 34398464
[TBL] [Abstract][Full Text] [Related]
34. FACTORS INFLUENCING THE SUCCESSFUL MAINTENANCE OF EUTHYROIDISM AFTER LOBECTOMY IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA: A SINGLE-CENTER STUDY.
Ha TK; Kim DW; Park HK; Lee YJ; Jung SJ; Baek HJ
Endocr Pract; 2019 Oct; 25(10):1035-1040. PubMed ID: 31241363
[No Abstract] [Full Text] [Related]
35. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
[TBL] [Abstract][Full Text] [Related]
36. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
Park S; Kim WG; Han M; Jeon MJ; Kwon H; Kim M; Sung TY; Kim TY; Kim WB; Hong SJ; Shong YK
Thyroid; 2017 Sep; 27(9):1164-1170. PubMed ID: 28699428
[TBL] [Abstract][Full Text] [Related]
37. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.
Moon JH; Ahn S; Seo J; Han JW; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Kim KW; Jang HC
J Clin Endocrinol Metab; 2014 Oct; 99(10):3782-9. PubMed ID: 25029415
[TBL] [Abstract][Full Text] [Related]
38. Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma.
Olveira G; Almaraz MC; Soriguer F; Garriga MJ; Gonzalez-Romero S; Tinahones F; Ruiz de Adana MS
Clin Endocrinol (Oxf); 1997 Jun; 46(6):707-11. PubMed ID: 9274701
[TBL] [Abstract][Full Text] [Related]
39. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
40. Monitoring thyroxine treatment during pregnancy.
Kaplan MM
Thyroid; 1992; 2(2):147-52. PubMed ID: 1525583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
